J&J’s Spravato nasal spray received a label expansion on Tuesday, now approved as a standalone treatment for major depressive ...

A new FDA warning letter for French pharmaceutical company Sanofi cited a handful of issues at its biologics factory in ...

Stanford University professor Irv Weissman and a colleague published a paper that represented a new way to target some ...

The Trump administration’s decision to withdraw from the World Health Organization could complicate US access to health ...

A father-and-son biotech with ties to Iceland and Philadelphia has put together a €26.5 million Series A to develop oral ...

Ascentage Pharma seeks $133M via US listing, markets olverembatinib in China with Takeda holding global rights. CEO Dajun ...

UnitedHealth's OptumRx to pass 100% of drug rebates to clients by 2028, but critics say GPO structure may still hide true ...

A revived legal challenge to the abortion pill mifepristone will be an early test for President Donald Trump’s administration ...

RTW forms Prolium to develop Keymed Biosciences' CD20×CD3 bispecific CM355 outside Asia for $17.5M upfront, part of growing ...

Sionna Therapeutics and Odyssey Therapeutics join Metsera and Maze in filing for IPOs, with Sionna focused on cystic fibrosis ...

Novo Nordisk’s blockbuster GLP-1 products Ozempic and Wegovy are among the next 15 drugs subject to the government’s Medicare ...

CMS didn't wait for President-elect Donald Trump to take office before issuing its second list of drugs to be negotiated ...